ChromoGenics conducts a rights issue of units for SEK 68.2 million
The Board of Directors of ChromoGenics AB (”ChromoGenics” or ”the Company”) has today, with support pursuant to the authorization granted by the Annual General Meeting on May 20, 2021, has decided to conduct an issue of units, consisting of shares and warrants of approximately SEK 68.2 million with preferential rights for existing shareholders (”the Rights Issue”). The terms of the Rights Issue mean that three (3) existing shares give the right to subscribe for one (1) unit, consisting of four (4) shares and four (4) warrants, at a subscription price of SEK 12.00, corresponding to SEK 3.00